SUMMARY The incidence of motor neurone disease in the Northern Region was studied for the year 1981 by means of hospital activity analysis records and questionnaire. The crude incidence rate was 2-2 per 100 000. This was not significantly different from the rate determined by using death certification. The age standardised incidence ratio for the region was 163 using the 1976 population and deaths from motor neurone disease in England and Wales as the reference. The female to male ratio was 1: 1 8 and the average age of diagnosis was 63 years. No meaningful intraregional variation was observed. Thus mortality appears to reflect incidence fairly accurately.
Motor neurone disease is a progressive illness with anterior horn cell and pyramidal tract involvement usually leading to death within five years. Annual incidence rates are approximately 1-0 per 100 000, and many studies have used death rates as an easier substitute for incidence because, with the short survival time, mortality rates should approach incidence rates.
A recent study gave figures that would result in an annual crude mortality rate of 1 6 per 100 000 for the area covered by the Northern Regional Health Authority.' Experience suggested that this figure was an underestimate, and, furthermore, intraregional variations were thought to exist with a higher incidence in the west of the region. The present study was therefore carried out to clarify the picture and to test the validity of using mortality as a proxy for incidence, by measuring as far as possible the actual incidence from admission and diagnosis in hospital. continues, and also reflects trends in the Northern region, then the figure of 10% would be further reduced. This feature is reassuring as it indicates that there has been no dramatic increase in incidence in the past three to five years, assuming that survival of the disease nationally is similarly reflected in the Northern Region. Atypical cases are unlikely to introduce significant errors between the number of cases diagnosed clinically and certified because such cases of motor neurone disease not diagnosed clinically would not be subsequently diagnosed post mortem. Likewise obvious cases having been missed clinically would also not be so certified, and death from another neurological disease erroneously attributed to motor neurone disease would raise figures but not necessarily mortality figures, because a necropsy may then reveal the true cause of the illness.
The mean age of diagnosis of 63 years and the female to male ratio of 1: 1 -8 accord with other recent studies.' 5
There was a "statistically significant" intra regional variation, but this result should be treated with extreme scepticism. Though an a priori hypothesis existed, because the result was significant only when compared with two districts with the lowest standardised incidence ratios, it is unlikely to be real. The numbers are also too small for much assurance to 20 be placed in the result. Though it is interesting in affecting only men, occupation has been implicated in its aetiology. Unfortunately, none of these factors can be easily invoked here.
This study has reassuringly validated the use of mortality as an adequate surrogate measure of incidence for this condition.
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International Conference on "Detection methods for DNA-damaging agents in man: Applications in cancer epidemiology and prevention" Espoo, Helsinki, Finland 2-4 September 1987 This conference, sponsored jointly by the International Agency for Research on Cancer (IARC) and the Institute of Occupational Health, Helsinki, will promote critical appraisal of methods for detecting DNA-damaging agents and their immediate effects in humans, their application in research into the causes of human cancer, and their use in monitoring the exposure of humans to known carcinogens. A particular objective of the conference is to foster, through multidisciplinary discussions, the use of these methods in future research in cancer epidemiology. Measurement methods discussed will include analysis of human tissues and body fluids for adducts of carcinogens with DNA, RNA and protein, and analyses for carcinogen-modified nucfeobases, thioethers, indicator nitrosamines, and mutagenic metabolites.
One session on measurement of the effects of alkylating agents will be dedicated to the honour of Professor L. Ehrenberg's scientific contributions to this and related subjects.
For further information and abstract/registration forms, please contact: K. Hemminki, Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland
